Susquehanna International Group LLP bought a new stake in VYNE Therapeutics Inc. (NASDAQ:VYNE – Free Report) in the second quarter, Holdings Channel.com reports. The institutional investor bought 118,957 shares of the company’s stock, valued at approximately $77,000. Susquehanna International Group LLP owned 0.18% of VYNE Therapeutics at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Two Sigma Securities LLC purchased a new position in shares of VYNE Therapeutics during the second quarter valued at $26,000. BlackRock Inc. purchased a new stake in VYNE Therapeutics in the 2nd quarter worth about $29,000. XTX Topco Ltd purchased a new stake in VYNE Therapeutics in the 4th quarter worth about $46,000. GSA Capital Partners LLP acquired a new stake in VYNE Therapeutics during the 2nd quarter worth about $47,000. Finally, Rangeley Capital LLC boosted its position in VYNE Therapeutics by 18.1% during the 1st quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock worth $71,000 after acquiring an additional 18,064 shares during the period. Institutional investors and hedge funds own 83.78% of the company’s stock.
VYNE Therapeutics Price Performance
NASDAQ:VYNE opened at $28.32 on Friday. The stock has a market cap of $18.98 million, a PE ratio of -74.54 and a beta of 2.00. VYNE Therapeutics Inc. has a fifty-two week low of $14.03 and a fifty-two week high of $79.75. The stock’s 50-day moving average is $31.40 and its two-hundred day moving average is $31.48.
VYNE Therapeutics Dividend Announcement
The business also recently disclosed a special dividend, which was paid on Thursday, July 23rd. Shareholders of record on Wednesday, July 22nd were paid a $19.00 dividend.
About VYNE Therapeutics
VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.
The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.
Read More
- Five stocks we like better than VYNE Therapeutics
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Want to see what other hedge funds are holding VYNE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VYNE Therapeutics Inc. (NASDAQ:VYNE – Free Report).
Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
